TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05817552

Intervention type: DIAGNOSTIC_TEST
Intervention: Geomagic Control X
Description: 3D Surface matching and compare

Intervention type: DIAGNOSTIC_TEST
Intervention: Geomagic Control X
Description: 3D Surface matching and compare

Intervention type: DIAGNOSTIC_TEST
Intervention: Geomagic Control X
Description: 3D Surface matching and compare
Study: NCT06106113

Intervention type: DRUG
Group type: OTHER
Intervention: GST-HG171 Tablets
Description: 150mg GST-HG171 Tablets

Intervention type: DRUG
Group type: OTHER
Intervention: GST-HG171 Tablets
Description: 150mg GST-HG171 Tablets

Intervention type: DRUG
Group type: OTHER
Intervention: GST-HG171 Tablets
Description: 150mg GST-HG171 Tablets
Study: NCT06431308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutritional intervention
Description: A nutrition guidance before initiation of AOM treatment include recommendations for food choices and eating habits to minimize the occurrence and severity of GI symptoms during the up-titration phase, will be given by registered dietitian (RD) from the study team. Next, each week, participants will provide weekly reports of GI symptoms occurrence and severity, by responding to queries sent via WhatsApp/SMS and for occurring symptoms, an automatically structured nutrition and behavioral treatment recommendations will be sent. Three days after each report of GI symptom(s), participants will receive an additional message and will be asked to report the occurrence and severity of the GI symptom, and their compliance with the specific dietary instructions received. If participants expressed an interest in personalized dietary guidance on this matter, the study team RD will contact him/her by telephone, within a range of 48 hours, to provide individualized recommendations
Study: NCT04811131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARQ-252 cream 0.3%
Description: ARQ-252 cream 0.3%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARQ-252 cream 0.3%
Description: ARQ-252 cream 0.3%
Study: NCT06461663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breast Cancer Locator Guided Breast Conserving Surgery
Description: Subjects will undergo a contrast-enhanced supine MRI and two marks will be placed on the breast. The MRI images will be transmitted to the sponsor, and the images will be used to build a BCL using 3D printing. Investigators will be provided with a 3D image of the cancer in the breast. Investigators will use a BCL (a patient-specific, plastic, bra-like form that is placed on the breast and allows the investigator to mark the edges of the tumor on the skin and to place wires inside the breast which define the center of the cancer and the tumor edges. The surgeon will then attempt to surgically remove all the tissue inside the wires used to define the tumor edges.
Study: NCT04946890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX2843
Description: MRX2843 is treated at 80mg/d, 120mg/d and 180mg/d respectively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX2843
Description: MRX2843 is treated at 80mg/d, 120mg/d and 180mg/d respectively
Study: NCT04811131

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARQ-252 Vehicle cream
Description: ARQ-252 Vehicle cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARQ-252 Vehicle cream
Description: ARQ-252 Vehicle cream

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB phototherapy active treatment
Description: NB-UVB phototherapy active treatment

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NB-UVB phototherapy active treatment
Description: NB-UVB phototherapy active treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB phototherapy sham treatment
Description: NB-UVB phototherapy sham treatment
Study: NCT04946890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX2843
Description: MRX2843 is treated at 80mg/d, 120mg/d and 180mg/d respectively
Study: NCT05262257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Take it regularly for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Take it regularly for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: patients did not take any hypoglycemic drugs and adopted diet, exercise and other lifestyle intervention measures to control blood sugar.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: patients did not take any hypoglycemic drugs and adopted diet, exercise and other lifestyle intervention measures to control blood sugar.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: patients did not take any hypoglycemic drugs and adopted diet, exercise and other lifestyle intervention measures to control blood sugar.
Study: NCT04811131

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NB-UVB phototherapy sham treatment
Description: NB-UVB phototherapy sham treatment
Study: NCT06342908

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and stool sample collection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Therapy
Description: Given PpDC vaccine ID

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Given IM
Study: NCT06155422

Intervention type: DRUG
Intervention: Cadonilimab
Description: recurrent or metastatic cervical cancer in the first, second or third lines Systematic treatment
Study: NCT05362968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Freeze-dried strawberry powder
Description: Whole strawberries are freeze-dried to form a powder with improved shelf life that will be used in this research study. Strawberry powder will be provided by the California Strawberry Commission (Watsonville, CA)
Study: NCT05897008

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMAB007
Description: for subcutaneous injection only

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Xolair
Description: for subcutaneous injection only
Study: NCT05251194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video laryngoscope at thyroid surgical position
Description: After induction of anesthesia and muscle relaxation, the patient will be positioned with a standard pillow to exposure neck for thyroid surgery (thyroid surgical position). Then, tracheal intubation will be performed with a McGrath video laryngoscope. During laryngoscopy with the McGrath video laryngoscope, the intubation practitioner will record the modified Cormack-Lehane grade and the percentage of glottic opening (POGO) score when it is assumed that a direct laryngoscope is used and when using the video laryngoscope, respectively.
Study: NCT05225129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood flow restriction exercise
Description: blood flow restricted exercise, resistance training will be applied, corresponding to 30% of 1 maximum repetition for 8 weeks, 2 days in a week
Study: NCT05381363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Interferon α2b
Description: Drug: Inhaled Interferon α2b; 1-2 years old: 1 dose, three times per day; 3-7 years old: 1 dose, four times per day; 7-18 years old: 2 doses, four times per day

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of care treatment will be provided based on the New Coronavirus Pneumonia Prevention and Control guideline (9th edition), published by National Health Commission of China
Study: NCT04485949

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IGV-001 Cell Immunotherapy
Description: IGV-001, an immunotherapeutic product that combines personalized whole tumor-derived cells with an antisense oligonucleotide (IMV-001) in implantable biodiffusion chambers.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in implantable biodiffusion chambers containing a predetermined inactive solution.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC): Radiation Therapy
Description: Radiation therapy administered per institutional standards.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care (SOC): Radiation Therapy
Description: Radiation therapy administered per institutional standards.
Study: NCT05508100

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO-108
Description: IO-108, intravenously, on Day 1 of each 21-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO-108 + pembrolizumab
Description: IO-108, intravenously, on Day 1 of each 21-day cycle. Pembrolizumab will be administered intravenously on Day 1 of each 21-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO-108 + pembrolizumab
Description: IO-108, intravenously, on Day 1 of each 21-day cycle. Pembrolizumab will be administered intravenously on Day 1 of each 21-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO-108 + tislelizumab
Description: IO-108, intravenously, on Day 1 of each 21-day cycle. Tislelizumab will be administered intravenously on Day 1 of each 21-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO-108 + tislelizumab
Description: IO-108, intravenously, on Day 1 of each 21-day cycle. Tislelizumab will be administered intravenously on Day 1 of each 21-day cycle.
Study: NCT05745298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xcite Clinical Station
Description: The abdominal functional electrical stimulation (AFES) will be conducted using the Xcite system. This is a battery-powered stimulator with up to 12 channels of cyclical stimulation. It is a task-specific modality to enhance mass practice during neurological re-education. The electrical stimulation will be applied to the abdominal and back muscles. In addition, participants will receive two specific respiratory muscle training exercises performed 3 days per week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xcite Clinical Station
Description: The abdominal functional electrical stimulation (AFES) will be conducted using the Xcite system. This is a battery-powered stimulator with up to 12 channels of cyclical stimulation. It is a task-specific modality to enhance mass practice during neurological re-education. The electrical stimulation will be applied to the abdominal and back muscles. In addition, participants will receive two specific respiratory muscle training exercises performed 3 days per week.
Study: NCT06233253

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Chart Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mindfulness Meditation
Description: Receive an online mindfulness intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05607914

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percussion massage
Description: percussion massage to the dominant leg hamstring muscle for 5 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: static stretching
Description: Static stretching to the dominant hamstring muscle for 5 minutes
Study: NCT04988386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acoramidis (AG10)
Description: Acoramidis (AG10) twice daily
Study: NCT04751110

Intervention type: OTHER
Group type: OTHER
Intervention: ultrasound guided rhomboid intercostal block
Description: A linear ultrasound probe was medially placed in the sagittal plane on the medial border of the scapula at the T5-T7 level. We inserted a 22-gauge needle into the fascial plane between the rhomboid major and intercostal muscles in a craniocaudal direction and injected 15 ml mixture of 0.25% bupivacaine with 8 mg of dexamethasone into the fascial plane.
Study: NCT06546813

Intervention type: OTHER
Intervention: scales and questionnaire administration
Description: evaluation of the quality of prosthetic intervention, verification of the adequacy of assistive devices, and outcomes measurement
Study: NCT05169762

Intervention type: OTHER
Intervention: standard treatment
Description: starndard treatment for transgender women
Study: NCT04719975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Fatigue (Stroop task)
Description: A modified Stroop task of approximately 60 min will be used in order to induce mental fatigue (MF). This will be based on their performance during the max test that was conducted during the familiarization session. In this task, which will be partitioned in 4 blocks of 468 stimuli, four colored words (rood, blauw, groen and geel) will be presented one at a time on a computer screen. The participants will be required to indicate the color of the word, ignoring the meaning of the word itself.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Fatigue (Stroop task)
Description: A modified Stroop task of approximately 60 min will be used in order to induce mental fatigue (MF). This will be based on their performance during the max test that was conducted during the familiarization session. In this task, which will be partitioned in 4 blocks of 468 stimuli, four colored words (rood, blauw, groen and geel) will be presented one at a time on a computer screen. The participants will be required to indicate the color of the word, ignoring the meaning of the word itself.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (Documentary)
Description: In the control task subjects will have to watch a documentary of 60 min on the same computer screen as the one used for the experimental trial. In order to avoid under- and over-arousal the subjects will have the opportunity to choose between several documentaries as proposed by the research team. During the control task physiological and psychological measures will be assessed at the same time points as during the mental fatigue trial.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (Documentary)
Description: In the control task subjects will have to watch a documentary of 60 min on the same computer screen as the one used for the experimental trial. In order to avoid under- and over-arousal the subjects will have the opportunity to choose between several documentaries as proposed by the research team. During the control task physiological and psychological measures will be assessed at the same time points as during the mental fatigue trial.
Study: NCT05684744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: The patients will receive oral roflumilast in a dose of 500 mcg per day for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: The patients will receive methotrexate in a dose of 0.2- 0.4 mg/kg/week for 12 weeks
Study: NCT06198322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet-rich Fibrin
Description: Platelet-rich Fibrin will be injected distal to the canine on the experimental side

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 will be injected distal to the canine on the experimental side
Study: NCT04520490

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Based Behavioral Treatment
Description: Children with obesity accompanied by at least one parent or caregiver will attend 24 weekly sessions. Most sessions will be held via video-conference and include 25-30 min. meetings between an interventionist and each child/parent pair to individualize treatment, followed by separate child and parent group meetings lasting 40 - 45 min. A select few sessions will be held in-person between an interventionist and each child/parent pair with no group session. Parents will serve as primary agents of change for their child and for themselves. Training will focus on food and physical activity education, parenting around food and physical activity, and use of behavioral skills (e.g., self-monitoring, environmental control, contingency management). Intervention groups of 8-12 children/families will be initiated every 3-6 mos. in study yrs. 2-3.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Family Based Behavioral Treatment
Description: Children with obesity accompanied by at least one parent or caregiver will attend 24 weekly sessions. Most sessions will be held via video-conference and include 25-30 min. meetings between an interventionist and each child/parent pair to individualize treatment, followed by separate child and parent group meetings lasting 40 - 45 min. A select few sessions will be held in-person between an interventionist and each child/parent pair with no group session. Parents will serve as primary agents of change for their child and for themselves. Training will focus on food and physical activity education, parenting around food and physical activity, and use of behavioral skills (e.g., self-monitoring, environmental control, contingency management). Intervention groups of 8-12 children/families will be initiated every 3-6 mos. in study yrs. 2-3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide 2 mg [Bydureon]
Description: Weekly injections of active drug.
Study: NCT04485949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC: Temozolomide
Description: Temozolomide administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOC: Temozolomide
Description: Temozolomide administered orally.
Study: NCT06393075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: combined care guidance
Description: Pain care guidance animation Rehabilitation exercise guidance animation Demonstrate how to perform rehabilitation exercises Demonstrate how to use a walker

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: general care guidance
Description: general care guidance
Study: NCT05990634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeChamps Platform
Description: Participants will be provided with the study equipment, i.e., a mobile app, smartwatch, smart t-shirt, smart scale, location home sensor, and a micro-computer, with which they will need to interact with the devices for three months in the respective study phase (pre-pilot/feasibility trial). Specifically, participants should wear the activity tracker wristband (Fitbit Charge 4) as much as possible. The smart t-shirt should as well be worn daily as much as possible. Additionally, participants should use the smart scale to weigh themselves and the mobile app to fill in selected PROMs monthly, while the ambient home sensors (location home sensor (LOCS) and smart plug) will be passively collecting information about their everyday living during these three months. Lastly, participants' clinical and demographic data from the local EHRs will be collected.
Study: NCT04520490

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weekly placebo injections
Study: NCT01998074

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: extensively hydrolyzed rice protein formula
Study: NCT06500637

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TB006
Description: TB006 is a humanized immunoglobulin G4 (IgG4) (S228P) type monoclonal antibody that is highly specific and has a high affinity to human Galectin-3 (hGal-3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB006
Description: TB006 is a humanized immunoglobulin G4 (IgG4) (S228P) type monoclonal antibody that is highly specific and has a high affinity to human Galectin-3 (hGal-3).
Study: NCT04512794

Intervention type: DEVICE
Group type: OTHER
Intervention: AcQMap High Resolution Imaging and Mapping System
Description: Evaluate the safety and effectiveness of the AcQMap System in mapping atrial arrhythmias when a specific procedure work flow is followed.
Study: NCT05702632

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1- Reciprocal electrical stimulation
Description: A specialized programmable electrical stimulation device was used (Uniphy is the manufacturer of Phyaction787; Uniphy, Eindhoven, the Netherlands). The device has two channels that can alternatively stimulate two opposing groups of muscles (reciprocate).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TheraTogs orthotic treatment
Description: A sleeveless top vest and two pairs of shorts with two thigh cuffs and limb cuffs each make up the TheraTogs strapping system which is applied to the children in the TheraTogs group. The TheraTogs suit is providing breathable, comfortable- Latex over the torso and thigh, as well as free toileting. For infection control and size fitting problems, participants are not allowed to share their TheraTogs with other patients. TheraTog's orthotic undergarment and strapping system were worn under their regular clothes, so it was neither distracting nor irritating.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy program
Description: Facilitation of balance and gait training

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy program
Description: Facilitation of balance and gait training
Study: NCT05068141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG001
Description: Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 240 mg, i.v., q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Paclitaxel for Injection (Albumin Bound), 100 mg/m\^2, i.v., D1, D8, D15 of every 4-week cycle
Study: NCT04582136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: In the double-blinded phase, sirolimus 1.5mg/day plus SOC is administered throughout 24 weeks; in the open-label extension period, patients who opt to participate continue on sirolimus 1.5mg/day plus SOC for an additional 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the double-blinded phase, placebo plus SOC is administered throughout 24 weeks; in the open-label extension period, patients who opt to participate are switched to receive sirolimus 1.5mg/day plus SOC for an additional 24 weeks.
Study: NCT05614193

Intervention type: DIAGNOSTIC_TEST
Intervention: Deep learning imaging enhancement
Description: Conventional imaging or down-sampling imaging from CT or MR are enhanced by approved deep learning method.